Broad Adds 22 New Units to Significantly Expand its Whole-Genome Sequencing Capacity

SAN DIEGO–Illumina, Inc. (NASDAQ:ILMN) today announced that the Broad Institute of MIT and Harvard has acquired 22 additional Genome Analyzers to increase its installed base of the Illumina sequencing platform to 47 units.

“We are excited to build on our strong relationship with Illumina,” said Eric S. Lander, Director of the Broad Institute of MIT and Harvard. “We also believe that this partnership will help accelerate the application of genomics to medical practice.”

“The Broad Institute’s decision to significantly scale their installed base of Genome Analyzers is a tremendous sign of their confidence in our ability to continue improving the performance and economics of the system,” said Christian Henry, Senior Vice President and Chief Financial Officer at Illumina.

Over the course of the year Illumina plans to increase the throughput of the Genome Analyzer to as much as 95 gigabases of highly accurate DNA sequence data per single run, or the equivalent of one whole human genome at 30 times coverage.

Designed for facilities of all sizes, the Illumina Genome Analyzer has been adopted across genome centers worldwide, plus individual research labs, core and service facilities, and biotechnology and pharmaceutical companies. The Genome Analyzer offers the highest rate of daily output and the simplest and most user-friendly workflow. The Genome Analyzer also offers the broadest set of supported applications, including those used to profile and discover novel transcripts, to create a high-resolution genome-wide map of DNA-protein binding sites and to sequence entire human genomes to greater than 30x coverage.

For more information about the Genome Analyzer and to read what customers are doing with Illumina’s sequencing technology, please visit https://www.illumina.com/sequencing.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of next-generation life-science tools and integrated systems for the analysis of genetic variation and biological function. Using our proprietary technologies, we provide a comprehensive line of products and services that currently serve the sequencing, genotyping, and gene expression markets, and we expect to enter the market for molecular diagnostics. Our customers include leading genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, and biotechnology companies. Our tools provide researchers around the world with the performance, throughput, cost effectiveness, and flexibility necessary to perform the billions of genetic tests needed to extract valuable medical information from advances in genomics and proteomics. We believe this information will enable researchers to correlate genetic variation and biological function, which will enhance drug discovery and clinical research, allow diseases to be detected earlier, and permit better choices of drugs for individual patients.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are Illumina’s ability (i) to develop and commercialize further our BeadArray™, VeraCode®, and Solexa® technologies and to deploy new sequencing, gene expression, and genotyping products and applications for our technology platforms, (ii) to manufacture robust instrumentation and reagents technology, together with other factors detailed in our filings with the Securities and Exchange Commission including our recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. We disclaim any intent or obligation to update these forward-looking statements beyond the date of this release.